6420 Annual Report 2005. qxd 28 4 06 17:44 Page 109 Notes to the Company balance sheet UK GAAP As at December 31, 2005 Foreign currency transactions Taxation Transactions in foreign currencies are recorded at the rate of exchange Current tax, including UK corporation tax and foreign tax, is provided ruling at the date of the transaction.
Monetary assets and liabilities at amounts expected to be paid or recovered using the tax rates and denominated in foreign currencies at the balance sheet dates are laws that have been enacted or substantively enacted by the balance reported at the rate of exchange prevailing at that date.
Exchange differences arising on translation of the opening net Deferred tax is recognised in respect of all timing differences that investments and on foreign currency borrowings, to the extent that they have originated but not reversed at the balance sheet date where hedge the Groups investment in such operations, are reported in the transactions or events that result in an obligation to pay more tax in statement of total recognised gains and losses.
the future or a right to pay less tax in the future have occurred at the balance sheet date.
Timing differences are differences between the Share-based compensation Companys taxable profits and its results as stated in the financial The company has applied the requirements of FRS 20, Sharebased statements that arise from the inclusion of gains and losses in tax Payments.
assessments in periods different from those in which they are recognised in the financial statements.
The Company operates equity-settled, share-based compensation plans.
The fair value of the employee services received in exchange A net deferred tax asset is regarded as recoverable and therefore for the grant of the options is calculated using the Black-Scholes model.
recognised only when, on the basis of all available evidence, it can In accordance with FRS 20, Share-based Payments, the resulting cost be regarded as more likely than not that there will be suitable taxable is recognised as an expense on a straight-line basis over the vesting profits from which the future reversal of the underlying timing period of the options.
The value of the charge is adjusted to reflect differences can be deducted.
expected and actual levels of options vesting.
Deferred tax is not provided in timing differences arising on unremitted The Company also provides employees with the option to purchase earnings of subsidiaries and associates where there is no commitment the Companys ordinary shares under the Shire Pharmaceuticals to remit these earnings.
Sharesave Scheme at an exercise price equal to 80% of the midmarket price on the day before invitations are issued to employees.
Deferred tax is measured at the rates that are expected to apply in the The proceeds received, net of any directly attributable transaction periods in which the timing differences are expected to reverse, based costs, are credited to share capital nominal value and share premium on tax rates and laws that have been enacted or substantively enacted when the options are exercised.
by the balance sheet date.
Deferred tax balances are not discounted.
Financial liabilities and equity The Company has also adopted FRS 25, Financial Instruments: Disclosure and Presentation and FRS 26, Financial Instruments: Measurement.
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into.
An equity instrument is any contract that evidences a residual interest in the assets of the Group after deducting all of its liabilities.
Annual report and accounts for the 109 year ended December 31, 2005 Shire plc 6420 Annual Report 2005. qxd 28 4 06 17:44 Page 110 Notes to the Company balance sheet UK GAAP As at December 31, 2005 C Intangible assets As at December 31, 2005 $000 At September 5, 2005 Additions in the period 443 At December 31, 2005 443 D Fixed asset investments As at December 31, 2005 $000 Shares in subsidiary undertakings At September 5, 2005 Additions in the period 3,088,781 At December 31, 2005 3,088,781 On November 25, 2005 the Company acquired the share capital of Shire Pharmaceuticals Group plc under the Scheme of Arrangement at a nominal value of 350 pence per share.
See Note I for further details.
Principal subsidiaries of the Group are shown in Note 36 of the Group accounts.
E Debtors As at As at December 31, September 5, 2005 2005 $000 $000 Amounts due from Group undertakings 13,420 Other debtors 189 86 13,609 86 F Creditors: Amounts falling due within one year As at As at December 31, September 5, 2005 2005 $000 $000 Amounts owed to Group undertakings 9,247 Other taxes and social security payable 320 Non-voting redeemable preference shares 86 86 Accruals and deferred income 24 9,677 86 The non-voting redeemable preference shares were issued at par on September 5, 2005.
The rights and restrictions attached to the non-voting redeemable preference shares are set out below: a Income The holders of the non-voting redeemable preference shares shall, with effect from the date of adoption of these articles, have the right to receive, out of the profits of the Company available for distribution and resolved to be distributed, a fixed non-cumulative preferential dividend at a rate of 5% per annum on the capital sum paid up thereon.
The non-voting redeemable preference shares shall rank for dividends in priority to any ordinary shares in the capital of the Company including, but not limited to, the subscriber ordinary shares from time to time in issue: 110 Annual report and accounts for the year ended December 31, 2005 Shire plc 6420 Annual Report 2005. qxd 28 4 06 17:44 Page 111 Notes to the Company balance sheet UK GAAP As at December 31, 2005 b Capital The holders of the non-voting redeemable preference shares on a return of capital on liquidation or otherwise shall be entitled to receive out of the assets of the Company available for distribution among the members the amounts paid up on those shares, together with any accrued but unpaid dividend on those shares, in priority to any distribution to any holder of ordinary shares in the Company including, but not limited to, the subscriber ordinary shares from time to time in issue: Except as provided in a and b above, the holders of the non-voting redeemable preference shares shall not have any other right to participate in the profits or assets in the Company: c Redemption 1 Subject to the provisions of the Companies Act, the Company shall redeem the non-voting redeemable preference shares A at any time at the discretion of the Directors of the Company: or B at any time after the earlier of a reduction of capital of the Company implemented subsequently to the Scheme becoming effective or June 30, 2006 at the request of the holders of the non-voting redeemable preference shares and shall on redemption pay the nominal amount paid up thereon together with any accrued but unpaid dividend on those shares provided always that if the Company shall at any time be unable, by reason of any provision of the Companies Acts, to redeem the non-voting redeemable preference shares on the date specified by the directors or requested by the holders of the non-voting redeemable preference shares, then the Company shall redeem such shares as soon as it is able to comply with such provisions of the Companies Acts: 2 Subject to sub-paragraph c 1 above, any notice of redemption served shall specify the date fixed for redemption and upon such date the holders of the non-voting redeemable preference shares shall present the certificate thereof in order that the same may be cancelled.
Upon such delivery the Company shall pay the holders the amount due to them in respect of such redemption.
d Transfer The Board may decline to register any transfer of any of the non-voting redeemable preference shares to any person they do not approve and decline to give any reason for that disapproval.
If the Board declines to register a transfer of any of the non-voting redeemable preference shares, they shall within two months after the date the transfer was lodged with the Company send to the transferee notice of their declining to register the transfer and the relevant instrument of transfer: e Voting The holders of the non-voting redeemable preference shares shall have no right as such to receive notice of or attend any general meeting of the Company unless a resolution is to be proposed to wind up the Company or a resolution is to be proposed which varies, modifies, alters or abrogates any of the rights of the non-voting redeemable preference shares.
G Share capital As at December 31, 2005 $000 Authorised 18,333,006,420 ordinary shares of 5 pence each 1,579,755 Called-up and allotted 495,733,782 ordinary shares of 5 pence each 42,728 Number $000 As at September 5, 2005 2 Issued in Scheme of Arrangement 495,173,820 2,987,532 Capital reduction 2,946,490 Issued on exercise of options for cash consideration 559,960 1,686 As at December 31, 2005 495,733,782 42,728 Authorised, called-up and allotted share capital as at September 5, was 2.00 $3.45.
Details of the Companys shares under option are shown in Note 31 of the Group accounts.
Annual report and accounts for the 111 year ended December 31, 2005 Shire plc 6420 Annual Report 2005. qxd 28 4 06 17:44 Page 112 Notes to the Company balance sheet UK GAAP As at December 31, 2005 H Movement on reserves Capital Share Exchangeable reduction Profit and premium shares reserve loss account $000 $000 $000 $000 As at September 5, 2005 Options exercised 2,977 Issue of exchangeable shares 101,248 Scheme of arrangement and capital reduction 2,946,490 Loss for period 363 Share-based compensation 76 As at December 31, 2005 2,977 101,248 2,946,490 287 On November 25, 2005, Shire plc, a public limited company incorporated in England and Wales Shire, became the holding company of Shire Pharmaceuticals Group plc SPG pursuant to a scheme of arrangement under section 425 of the UK Companies Act 1985 that was approved by the High Court of Justice in England and Wales and the shareholders of SPG the Scheme of Arrangement.
Pursuant to the Scheme of Arrangement, ordinary shares, each having a nominal value of 3.50, of Shire Shire Ordinary Shares were exchanged for ordinary shares, each having a nominal value of 0.05 of SPG SPG Ordinary Shares, on a one-for-one basis.
As a result of the Scheme of Arrangement, SPG now renamed Shire Pharmaceuticals Group Limited is now a wholly-owned subsidiary of Shire.
The Shire Ordinary Shares carry substantially the same rights as did the SPG Ordinary Shares.
The Scheme of Arrangement did not involve any payment for the new Shire Ordinary Shares.
On November 28, 2005 the High Court of Justice in England and Wales approved a reduction of Shires share capital to take effect on November 29, 2005, when the nominal value of each Shire ordinary share was reduced from 3.50 pence to 0.05 pence.
This gave rise to a capital reduction reserve of $2,946,490,000, which is distributable.
I Reconciliation of movements in shareholders funds $000 Balance as at September 5, 2005 Shares issued in Scheme of Arrangement 2,987,532 Loss for the period 363 Employee share-based compensation: value of employee services 76 proceeds from shares issued 4,663 Issue of exchangeable shares 101,248 3,093,156 112 Annual report and accounts for the year ended December 31, 2005 Shire plc
